Anti-inflammatory therapy in the neonatal intensive care unit: present and future

Area of Science:

• Neonatal Medicine
• Pediatric Inflammation

Background:

• Neonatal inflammation is associated with numerous adverse health outcomes.
• Chorioamnionitis, a major inflammatory source, often precedes delivery, limiting the impact of postnatal interventions.
• Preterm infants face significant exposure to postnatal inflammatory stimuli.

Purpose of the Study:

• To review major sources of neonatal inflammation.
• To discuss methods for reducing inflammatory exposure in newborns.
• To evaluate current anti-inflammatory drug therapies and explore future research directions.

Main Methods:

• Literature review of inflammation sources, exposure reduction, and anti-inflammatory therapies.
• Analysis of the efficacy of interventions like mechanical ventilation and sepsis management.
• Examination of current drug therapies, including dexamethasone and erythromycin for Ureaplasma urealyticum.

Main Results:

• Postnatal interventions may not fully mitigate outcomes related to pre-delivery inflammation like chorioamnionitis.
• Reducing exposure to postnatal inflammatory stimuli may be more effective than drug therapy.
• Dexamethasone is the only proven drug to decrease extubation failure and bronchopulmonary dysplasia (BPD), but has side effects. Erythromycin has been ineffective against BPD.

Conclusions:

• Strategies to reduce exposure to postnatal inflammatory stimuli are crucial for improving outcomes in preterm infants.
• Future research should focus on targeted glucocorticoid therapies and novel agents inhibiting specific pro-inflammatory pathways.
• Optimizing anti-inflammatory strategies requires a nuanced approach considering drug side effects and intervention efficacy.